Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate

American Journal of Transplantation

Volumn 11, Issue 8, 2011, Pages 1559-1560

  Forns, X ^a   Navasa, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Fibrosis; hepatitis C; immunosuppression; interferon; outcomes; sustained virological response

Indexed keywords

BOCEPREVIR; CYCLOPHILIN; CYCLOSPORIN A; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TACROLIMUS; TELAPREVIR;

BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GINGIVA HYPERTROPHY; GRAFT SURVIVAL; HEPATITIS C; HIRSUTISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIPID METABOLISM; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

CYCLOSPORINE; DATABASE MANAGEMENT SYSTEMS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; TACROLIMUS; TREATMENT OUTCOME;

EID: 79961094863     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03511.x     Document Type: Editorial

References (13)

1. Lake JR,. Immunosuppression and outcomes of patients transplanted for hepatitis C. J Hepatol 2006; 44: 627-629.
2. O'Grady JG, Hardy P, Burroughs AK, Elbourne D,. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: Poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-141. (Pubitemid 44952866)
3. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL,. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; CD005161.
4. Berenguer M, Crippin J, Gish R, et al,. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34-41. (Pubitemid 36775793)
5. Berenguer M, Aguilera V, Prieto M, et al,. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-767.
6. Berenguer M, Aguilera V, San JF, et al,. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209.
7. Irish W, Arcona S, Bowers D, Trotter J,. Cyclosporine versus tacrolimus treated liver transplant recipients with hepatitis C: Outcome analysis of the UNOS/OPTN database. Am J Transplant 2011.
8. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687. (Pubitemid 351287553)
9. Carrion JA, Navasa M, Garcia-Retortillo M, et al,. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-1756. (Pubitemid 46695723)
10. Ciesek S, Steinmann E, Wedemeyer H, et al,. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 2009; 50: 1638-1645.
11. Cescon M, Grazi GL, Cucchetti A, et al,. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782-789.
12. Firpi RJ, Zhu H, Morelli G, et al,. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51-57.
13. Selzner N, Renner EL, Selzner M, et al,. Antiviral treatment of recurrent hepatitis C after liver transplantation: Predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.